Key facts
- This page summarizes Richard E. Uihlein's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Feb 2022, 08:25.
Richard E. Uihlein - 24 Jan 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- GALT
- Reported as of
- 24 Jan 2022
- Net transaction value
- +$35,000
- SEC form
- 4
- Accepted by SEC
- 08 Feb 2022, 08:25:01 UTC
- Prior SEC filing
- 25 Jan 2022
- Next SEC filing
- 30 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- Jack W. Callicutt
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard E. Uihlein filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 08 Feb 2022.
Change
- Previous filing in this sequence was filed on 25 Jan 2022.
- Current net transaction value: +$35,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GALT
transaction
Common Stock
Award
- Transaction value
- $35,000
- Shares
- +17,677
- Change %
- +0.22%
- Price
- $1.98
- Shares after
- 7,936,677
- Date
- 24 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
GALT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 27,710
- Date
- 24 Jan 2022
- Ownership
- By Ed Uihlein Family Foundation
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GALT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 24 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $1.98
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022.
Footnote F2
The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
Footnote F3
The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
Footnote F4
The options vest 100% on December 31, 2022.